PetMed Express (NASDAQ:PETS) Cut to Hold at StockNews.com

StockNews.com lowered shares of PetMed Express (NASDAQ:PETS) from a buy rating to a hold rating in a research note issued to investors on Wednesday morning.

Separately, Morgan Stanley reduced their price target on shares of PetMed Express from $3.50 to $3.20 and set an “underweight” rating for the company in a research report on Thursday, April 17th.

PetMed Express Stock Performance

Shares of NASDAQ PETS opened at $3.64 on Wednesday. The stock has a fifty day moving average of $3.65 and a 200-day moving average of $4.43. The stock has a market cap of $75.19 million, a PE ratio of 364.36 and a beta of 0.76. PetMed Express has a fifty-two week low of $2.90 and a fifty-two week high of $6.85.

PetMed Express (NASDAQ:PETS) last announced its quarterly earnings results on Monday, February 10th. The company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.02). PetMed Express had a return on equity of 0.37% and a net margin of 0.14%. On average, sell-side analysts predict that PetMed Express will post 0.19 EPS for the current year.

Insider Transactions at PetMed Express

In other PetMed Express news, CEO Sandra Yvette Campos sold 60,463 shares of PetMed Express stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $3.31, for a total transaction of $200,132.53. Following the completion of the sale, the chief executive officer now directly owns 578,524 shares in the company, valued at $1,914,914.44. The trade was a 9.46 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.10% of the stock is owned by insiders.

Institutional Trading of PetMed Express

Several institutional investors and hedge funds have recently made changes to their positions in PETS. Arrowstreet Capital Limited Partnership increased its stake in PetMed Express by 26.5% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 513,381 shares of the company’s stock valued at $2,474,000 after acquiring an additional 107,614 shares during the last quarter. Metavasi Capital LP increased its position in shares of PetMed Express by 48.5% during the 4th quarter. Metavasi Capital LP now owns 340,302 shares of the company’s stock valued at $1,640,000 after purchasing an additional 111,194 shares during the last quarter. Geode Capital Management LLC increased its position in shares of PetMed Express by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 224,788 shares of the company’s stock valued at $1,084,000 after purchasing an additional 3,558 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of PetMed Express by 2.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 216,812 shares of the company’s stock valued at $1,045,000 after buying an additional 4,410 shares in the last quarter. Finally, Man Group plc lifted its position in PetMed Express by 5.5% in the 4th quarter. Man Group plc now owns 145,796 shares of the company’s stock worth $703,000 after buying an additional 7,646 shares during the last quarter. Hedge funds and other institutional investors own 73.33% of the company’s stock.

About PetMed Express

PetMed Express, Inc, together with its subsidiaries, operates as a pet pharmacy in the United States. The company markets prescription and non-prescription pet medications, health products, and other supplies for dogs, cats, and horses. It offers non-prescription medications and supplies, such as flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and household pet supplies; and prescription medications, including heartworm preventatives, flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.